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What is Radium 223?
Energy α-energy
5,78 MeV
t1/2 11,4 d
Parent nuclide 227Ac
Radiopharmaceutical 223RaCl2
Usage Prostate cancer
Bone cancer
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Limitations of Radium 223 radiopharmaceuticals
• Bone marrow suppression
• Anemia, lymphocytopenia, leukopenia, thrombocytopenia and
neutropenia
• Nausea, diarrhea, vomiting
• Swelling of the legs, ankles, or feet
• Dehydration, injection site reactions (redness, pain, swelling)
• Kidney impairment
From reality to dreams
Characteristics and known 
data about 223Ra in trials 
Ideal 223Ra 
radiopharmaceutical agent 
Conclusion
• For urologists dedicated to CRPC patient care, radium- 223 is an
important therapeutic option for treating patients with
symptomatic bone metastases
• Ra-223 is the first radiopharmaceutical to both prolong survival
and provide pain relief, as well as reduce skeletal morbidity in
patients with CRPC and bone metastases compared with placebo
and best supportive care alone
• The safety profile has been established, specifically demonstrating
a low incidence of myelosuppression (≥3%)
• Can pass throw blood-brain barrier
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